Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Hispanics/Latinos with non-small cell lung cancer have higher overall survival rates

Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival compared to non-Hispanic white patients, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Married patients with locally advanced lung cancer likely to survive longer after treatment

Married patients with locally advanced lung cancer are likely to survive longer after treatment than patients who are single, according to a study by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.

7 Sep 2012

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Melanoma manifests differently in children than in adults

Melanoma, newly diagnosed in more than 76,000 Americans in 2011, is the most common and dangerous form of skin cancer. Melanoma is rare in children, accounting for 1 to 4 percent of all melanoma cases and just 3 percent of pediatric cancers. Just as adult cases of melanoma are increasing, pediatric melanoma is rising at the rate of 1 to 4 percent per year.

7 Sep 2012

Race, marital status can impact survival rates of patients with Stage III non-small cell lung cancer

A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

'Toolkit' for African cancer advocates to be launched on September 15

Cancer kills more than seven million people a year throughout the world. This is more than HIV/AIDS, tuberculosis and malaria combined, and African countries, which carry a large part of the burden, are the least able of all developing countries to cope with the challenges it presents, says a consortium of international cancer organizations.

7 Sep 2012

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

7 Sep 2012

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

7 Sep 2012

Hopes dashed for ginkgo biloba in Alzheimer’s disease

The GuidAge trial of ginkgo biloba extract in people with evidence of memory problems confirms that the treatment does not reduce their risk for progression to Alzheimer’s disease.

6 Sep 2012

Better recognition of rising burden of cancer in Africa needed

6 Sep 2012

Scientists complete comprehensive map of genetic mutations linked to small cell lung cancers

Scientists have completed a comprehensive map of genetic mutations linked to an aggressive and lethal type of lung cancer.

6 Sep 2012

Janssen, ImmuNext partner to develop novel cancer therapeutics

ImmuNext, Inc., today announced that it has entered into an agreement with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer.

6 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

Oncology News and Research

Further Reading

Hispanics/Latinos with non-small cell lung cancer have higher overall survival rates

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Married patients with locally advanced lung cancer likely to survive longer after treatment

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Melanoma manifests differently in children than in adults

Race, marital status can impact survival rates of patients with Stage III non-small cell lung cancer

'Toolkit' for African cancer advocates to be launched on September 15

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Hopes dashed for ginkgo biloba in Alzheimer’s disease

Better recognition of rising burden of cancer in Africa needed

Scientists complete comprehensive map of genetic mutations linked to small cell lung cancers

Janssen, ImmuNext partner to develop novel cancer therapeutics

Sorafenib could be effective against multiple myeloma

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News